Regeneron Pharmaceuticals Inc. buy Jefferies Financial Group Inc.
Summary
This prediction is currently active. The BUY prediction by Jefferies_Financial_ currently has a performance of 21.06%. Dividends of €0.88 are taken into consideration when calculating the performance. This prediction currently runs until 27.08.26. The prediction end date can be changed by Jefferies_Financial_ at any time. Jefferies_Financial_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | -5.956% | -5.956% |
| iShares Core DAX® | -1.875% | 2.861% |
| iShares Nasdaq 100 | -2.177% | 0.048% |
| iShares Nikkei 225® | -0.867% | 6.987% |
| iShares S&P 500 | -1.253% | 1.248% |
Comments by Jefferies_Financial_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Jefferies_Financial_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
28.11.23
28.11.24
29.11.24

